Management of Dyslipidemia with Statins in the Patient with Peripheral Arterial Disease

被引:3
作者
Blum, Andrew S. [1 ]
机构
[1] Elmhurst Mem Hosp, Div Vasc Intervent Radiol, 200 Berteau Ave, Elmhurst, IL 60126 USA
关键词
dyslipidemia; statins; atherosclerosis; peripheral arterial disease;
D O I
10.1053/j.tvir.2006.12.004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The relationship between peripheral arterial disease (PAD), cardiovascular disease (CAD), and underlying atherosclerotic risk factors such as dyslipidemia, smoking, diabetes, and hypertension is well established. Patients with PAD have dramatically increased risks of cardiovascular mortality due to underlying atherosclerosis. As interventionalists, we focus primarily on improving the functional status of our patients by "fixing" their peripheral arterial occlusions, often ignoring the more serious concerns, as well as the root cause of the problem. In addition to interventional strategies, comprehensive clinical management of PAD should include attention to risk factor modification, lifestyle changes, exercise therapy, and pharmacologic interventions. Conventional training in interventional radiology imparts very little familiarity with these management issues. The following article addresses one critical modifiable risk factor, dyslipidemia, and treatment with the powerful class of drugs, the statins, reviewing the rationale for as well as the practical considerations in the use of these agents. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:50 / 55
页数:6
相关论文
共 42 条
[1]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]  
Baker SK, 2001, CLIN INVEST MED, V24, P258
[3]   A general assessment of the safety of HMG CoA reductase inhibitors (statins). [J].
Black D.M. .
Current Atherosclerosis Reports, 2002, 4 (1) :34-41
[4]   EFFECTS OF COLESTIPOL-NIACIN THERAPY ON HUMAN FEMORAL ATHEROSCLEROSIS [J].
BLANKENHORN, DH ;
AZEN, SP ;
CRAWFORD, DW ;
NESSIM, SA ;
SANMARCO, ME ;
SELZER, RH ;
SHIRCORE, AM ;
WICKHAM, EC .
CIRCULATION, 1991, 83 (02) :438-447
[5]   Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH) [J].
Buchwald, H ;
Bourdages, HR ;
Campos, CT ;
Nguyen, P ;
Williams, SE ;
Boen, JR .
SURGERY, 1996, 120 (04) :672-679
[6]  
Byington RP, 2001, CIRCULATION, V103, P387
[7]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[8]   HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].
CLARKE, R ;
DALY, L ;
ROBINSON, K ;
NAUGHTEN, E ;
CAHALANE, S ;
FOWLER, B ;
GRAHAM, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155
[9]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3